Angiotensin III (human, mouse): Core RAAS Peptide for Cardiovascular and Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) is a biologically active hexapeptide (sequence: Arg-Val-Tyr-Ile-His-Pro-Phe) that mediates approximately 40% of the pressor activity of angiotensin II and fully retains aldosterone-stimulating capability (Oliveira et al., 2025). It interacts with both AT1 and AT2 angiotensin receptors, with relative specificity for AT2, and exogenous application induces aldosterone secretion while suppressing renin release [DOI]. Angiotensin III (human, mouse) is highly soluble and suitable for cardiovascular and neuroendocrine research, with validated use in rodent models [APExBIO]. Proper storage as a solid at -20°C ensures maximal stability and reproducibility. Recent evidence also links angiotensin peptides to modulation of viral pathogenesis, providing additional translational value [DOI].

Biological Rationale

Angiotensin III (human, mouse) is generated in vivo by N-terminal cleavage of angiotensin II through angiotensinase activity in erythrocytes and tissues (Oliveira et al., 2025). It is a key effector in the renin-angiotensin-aldosterone system (RAAS), a hormonal cascade that regulates blood pressure, electrolyte balance, and fluid homeostasis [DOI]. The peptide's sequence (Arg-Val-Tyr-Ile-His-Pro-Phe) is conserved between human and mouse, supporting its translational relevance [APExBIO]. Unlike angiotensin II, angiotensin III is more selectively active at the AT2 receptor, which is implicated in vasodilation, anti-fibrotic, and anti-inflammatory effects, partially counterbalancing AT1-mediated responses [DOI]. The pressor and dipsogenic effects observed in rodent models further anchor its role in neuroendocrine regulation [More: RAAS Core Peptide].

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III acts by binding to AT1 and AT2 receptors, both members of the G protein-coupled receptor (GPCR) family (Oliveira et al., 2025). AT1 receptor activation triggers vasoconstriction, sodium retention, aldosterone secretion, and sympathetic nervous system stimulation. AT2 receptor activation, in contrast, mediates vasodilation, natriuresis, and anti-proliferative effects. Angiotensin III retains full aldosterone-stimulating capacity, matching angiotensin II, and mediates about 40% of angiotensin II's pressor effect in vivo [DOI]. In experimental systems, exogenous angiotensin III suppresses renin release through negative feedback mechanisms [DOI]. The peptide's capacity to induce pressor and dipsogenic responses in rodent CNS models is leveraged in neuroendocrine research [Contrast: Translational Keystone]. Notably, recent findings show that N-terminal deletions of angiotensin II, yielding angiotensin III, enhance spike–AXL binding in SARS-CoV-2 infection models, suggesting additional roles in viral pathogenesis [DOI].

Evidence & Benchmarks

• Angiotensin III (2–8) induces aldosterone secretion in vitro and in vivo, equivalent to angiotensin II levels (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• It mediates ~40% of the pressor response of angiotensin II in animal models under controlled infusion (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• Exogenous angiotensin III application suppresses renin release, confirming negative feedback in the RAAS network (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• In rodent brain studies, angiotensin III administration elicits both pressor and dipsogenic (thirst-inducing) responses (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• Peptide solubility benchmarks: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, ≥93.1 mg/mL in DMSO (APExBIO, https://www.apexbt.com/angiotensin-iii-human-mouse.html).
• Angiotensin III enhances the binding of SARS-CoV-2 spike protein to AXL, indicating possible roles in COVID-19 pathophysiology (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is widely used in mechanistic cardiovascular and neuroendocrine research. It is a validated tool for dissecting RAAS signaling, receptor pharmacology, and for modeling hypertension or aldosterone-driven pathologies [See: Advanced Benchmarking]. Compared to angiotensin II, it provides specific insights into AT2 receptor actions and negative feedback on renin release. Its role in modulating SARS-CoV-2 spike protein binding opens new translational applications [DOI]. However, Angiotensin III is not a direct substitute for angiotensin II in all contexts and should not be used for long-term solution storage due to stability limitations [APExBIO].

Common Pitfalls or Misconceptions

• Angiotensin III does not fully replace angiotensin II for studies requiring maximal pressor response; it mediates only ~40% of the effect.
• It is not suitable for long-term solution storage; solid, desiccated storage at -20°C is mandatory for stability.
• The peptide's effects are context-dependent; species, tissue, and receptor expression may alter outcomes.
• It does not exhibit direct antiviral properties, despite its modulation of spike–AXL binding in SARS-CoV-2 models.
• Over-reliance on receptor selectivity claims may be misleading; both AT1 and AT2 are engaged but with differential efficacy.

Workflow Integration & Parameters

APExBIO’s Angiotensin III (human, mouse) (SKU: A1043) is supplied as a solid with a molecular weight of 931.09 and chemical formula C46H66N12O9. For in vitro applications, dissolve in water (≥23.2 mg/mL), ethanol (≥43.8 mg/mL), or DMSO (≥93.1 mg/mL). Use freshly prepared solutions for optimal activity [A1043 kit]. Store the lyophilized peptide desiccated at -20°C. Avoid repeated freeze-thaw cycles and long-term solution storage. For cardiovascular studies, typical dosing in rodents mirrors published benchmarks (see Evidence & Benchmarks). Validate activity in each workflow, as minor lot-to-lot variations can impact results. This product is optimized for reproducibility and high-purity performance in preclinical models [Product Performance]. Compared to other articles such as this translational overview, which synthesizes broader mechanistic and clinical insights, the present article emphasizes atomic, verifiable facts and workflow specifics for immediate lab use.

Conclusion & Outlook

Angiotensin III (human, mouse) is an indispensable research tool for dissecting RAAS function, AT1/AT2 receptor pharmacology, and aldosterone regulation. Its validated performance and robust solubility support diverse experimental paradigms in cardiovascular and neuroendocrine fields. Ongoing research into angiotensin peptides’ interactions with viral proteins underscores the translational potential of this molecule. When sourced from established suppliers such as APExBIO, researchers gain access to reproducible, high-purity material critical for hypothesis-driven investigation. For detailed product specifications or to order, see Angiotensin III (human, mouse) A1043.